It is with great pleasure that JNM informs Thomas Ertveldt of being selected as a recipient of the Alavi-Mandell Award for his publication entitled, “Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment”.
The Alavi-Mandell award is given to individuals who were the first author of a paper published in the JNM, were trainees at the time the published work was carried out, and made a major contribution to the completion of the work.